5-Methoxy-psoralen for epidermal cell proliferation tumours

摘要

Medicament for topical treatment of epidermic proliferation cancerous tumours contains 5-methoxy psoralen, (I), in concentrations of 1000-10,000 ppm, with a suitable vehicle. The compsns. pref. contain a penetration agent, such as dimethylsulphoxide (DMSO). Medicaments for oral treatment of pre-cancerous or cancerous tumours contain (I) in doses of 200-400 mg. (I) is a known cpd. (see FR applications 77.31719) which may be applied topically, at concentrations of 100-1000 ppm, for the treatment of psoriasis, vitiligo, atypic eczema and fungoid mycosis. pref. in association with UV irradiation, and may be administered orally in daily doses of 20-300 mg. Epidermic cell proliferation tumours, such as baso-cellular epithelioma, spino-cellular epithelioma, Hutchinson reddening actinic hyperkeratosis, cutaneous melanoma etc. are caused by solar irradiation and the above treatment was considered unsuitable. The present invention uses 10-100 times higher concentrations of (I) to treat these tumours topically. (I) is well tolerated at these high concentrations. Clinical tests show that (I) can be administered orally, in daily doses of 400-800 mg/kg and gives good results with no toxicity problems.